Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) and Tenax Therapeutics Inc. (NASDAQ:TENX) compete against each other in the Biotechnology sector. We will compare them and contrast their analyst recommendations, profitability, institutional ownership, risk, dividends, earnings and valuation.
Earnings & Valuation
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Vertex Pharmaceuticals Incorporated||200||1.55||256.83M||2.29||72.86|
|Tenax Therapeutics Inc.||1||0.00||6.30M||-7.65||0.00|
In table 1 we can see Vertex Pharmaceuticals Incorporated and Tenax Therapeutics Inc.’s gross revenue, earnings per share (EPS) and valuation.
Table 2 provides the return on assets, return on equity and net margins of the two firms.
|Net Margins||Return on Equity||Return on Assets|
|Vertex Pharmaceuticals Incorporated||128,101,152.18%||0%||0%|
|Tenax Therapeutics Inc.||517,921,736.27%||-175.2%||-156.5%|
Risk & Volatility
Vertex Pharmaceuticals Incorporated has a 1.39 beta, while its volatility is 39.00%, thus making it more volatile than Standard & Poor’s 500. Competitively, Tenax Therapeutics Inc.’s 40.00% volatility makes it more volatile than Standard & Poor’s 500, because of the 1.4 beta.
Vertex Pharmaceuticals Incorporated’s Current Ratio is 3.8 while its Quick Ratio is 3.7. On the competitive side is, Tenax Therapeutics Inc. which has a 11 Current Ratio and a 11 Quick Ratio. Tenax Therapeutics Inc. is better positioned to pay off short and long-term obligations compared to Vertex Pharmaceuticals Incorporated.
The table delivered features the ratings and recommendations for Vertex Pharmaceuticals Incorporated and Tenax Therapeutics Inc.
|Sell Ratings||Hold Ratings||Buy Ratings||Rating Score|
|Vertex Pharmaceuticals Incorporated||0||1||15||2.94|
|Tenax Therapeutics Inc.||0||0||0||0.00|
Vertex Pharmaceuticals Incorporated’s upside potential currently stands at 3.81% and an $229.56 average target price.
Institutional and Insider Ownership
Institutional investors held 97.8% of Vertex Pharmaceuticals Incorporated shares and 22.2% of Tenax Therapeutics Inc. shares. 0.1% are Vertex Pharmaceuticals Incorporated’s share held by insiders. Competitively, 4.73% are Tenax Therapeutics Inc.’s share held by insiders.
In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.
|Performance (W)||Performance (M)||Performance (Q)||Performance (HY)||Performance (Y)||Performance (YTD)|
|Vertex Pharmaceuticals Incorporated||-3.88%||-8.37%||-3.46%||-10.92%||-4.47%||0.55%|
|Tenax Therapeutics Inc.||-2.96%||-6.43%||-21.56%||11.97%||-79.3%||8.26%|
For the past year Vertex Pharmaceuticals Incorporated’s stock price has smaller growth than Tenax Therapeutics Inc.
Vertex Pharmaceuticals Incorporated beats Tenax Therapeutics Inc. on 8 of the 12 factors.
Vertex Pharmaceuticals Incorporated discovers, develops, manufactures, and commercializes medicines for serious diseases. The company focuses on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs. It markets ORKAMBI (lumacaftor in combination with ivacaftor) for the treatment of patients with CF 12 years of age and older who have two copies (homozygous) of the F508del mutation in their cystic fibrosis transmembrane conductance regulator (CFTR) gene; and KALYDECO (ivacaftor) for the treatment of patients with CF 2 years of age and older who have the G551D mutation or other specified mutations in their CFTR gene. The company also develops Tezacaftor (VX-661), a corrector compound that is in a Phase III development program in combination with ivacaftor in multiple CF patients; VX-152 and VX-440 that are CFTR corrector compounds in Phase II clinical trials, as well as VX-659 and VX-445 that are CFTR corrector compounds in Phase I clinical trials; and VX-371, an investigational epithelial sodium channel, which is in a Phase II development program. In addition, it engages in the research and mid-and early-stage development programs in the areas of oncology, pain, and neurology. The company sells its products primarily to specialty pharmacy providers and wholesalers in North America, as well as government-owned and supported customers internationally. Vertex Pharmaceuticals Incorporated has collaborations with Cystic Fibrosis Foundation Therapeutics Incorporated; Parion Sciences, Inc.; CRISPR Therapeutics AG; Moderna Therapeutics, Inc.; BioAxone Biosciences, Inc.; Merck KGaA; and Janssen Pharmaceuticals, Inc. The company was founded in 1989 and is headquartered in Boston, Massachusetts.
Tenax Therapeutics, Inc., a specialty pharmaceutical company, focused on the identification, development, and commercialization of a portfolio of products for the critical care market in the United States and Canada. It focuses on the development and commercialization of pharmaceutical products containing levosimendan, 2.5 mg/ml concentrate for solution for infusion/5ml vial for use in the reduction of morbidity and mortality in cardiac surgery patients at risk for developing Low Cardiac Output Syndrome. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is headquartered in Morrisville, North Carolina.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.